Reversal of warfarin-induced hemorrhage in the emergency department

Meena Zareh, Andrew Davis, Sean Henderson, Meena Zareh, Andrew Davis, Sean Henderson

Abstract

Warfarin, an oral vitamin K antagonist, is used to prevent arterial and venous thromboembolism in patients suffering from a multitude of diseases. In 2004, 31 million warfarin prescriptions were dispensed in the United States. Warfarin inhibits the activation of the vitamin K-dependent clotting factors (Factors II, VII, IX, and X) and regulatory proteins (proteins C, S, and Z). It is one of the leading drugs implicated in emergency room visits for adverse drug reactions. Annually the frequency of bleeding complications associated with overanticoagulation is 15% to 20%, with fatal bleeds measuring as high as 1% to 3%. The most effective method of warfarin reversal involves the use of Four Factor Prothrombin Complex Concentrate (PCC), which is widely used throughout Europe but is unavailable in the United States. The current therapies available to emergency room physicians in the United States are fresh frozen plasma, recombinant Factor VIIa (rFVIIa), Factor Eight Inhibitory Bypassing Activity, or Three Factor PCC concomitantly administered with vitamin K. We review the advantages and disadvantages of these therapies and recommend Three Factor PCC with small doses of rFVIIa and with vitamin K in life-threatening situations if Four Factor PCC is unavailable.

Conflict of interest statement

Conflicts of Interest: By the WestJEM article submission agreement, all authors are required to disclose all affiliations, funding sources, and financial or management relationships that could be perceived as potential sources of bias. The authors disclosed none.

Figures

Figure 1.
Figure 1.
Coagulation cascade. * indicates vitamin K–dependent coagulation factors.
Figure 2.
Figure 2.
Vitamin K–dependent factors that are replenished with the use of recombinant Factor VIIa, fresh frozen plasma, Three-Factor Prothrombin Complex Concentrate (PCC), Four-Factor PCC, and Factor Eight Inhibitor Bypass Activity.

References

    1. Kaufman DW, Kelly JP, Rosenberg L, et al. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone Survey. J Am Med Assoc. 2002;;287:337–344.
    1. Baglin TP, Keeling DM, Watson HG. Guidelines on oral anticoagulation (warfarin): third edition–2005 update. Br Soc Haematol. 2005;;132:277–285.
    1. Hirsch J, Fuster V, Ansell J, et al. American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy. J Am Coll Cardiol. 2003;;41:1633–1652.
    1. Schulman S. Care of patients receiving long-term anticoagulant therapy. N Engl J Med. 2003;;349:675–683.
    1. Ansell J, Hirsch J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th ed.) Chest. 2008;;133:160–198.
    1. Fihn SD, Callahan CM, Martin DC, et al. The risk for and severity of bleeding complications in elderly patients treated with warfarin. Ann Intern Med. 1996;;124:970–979.
    1. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT) Lancet. 1996;;348:423–428.
    1. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med. 1998;;105:91–99.
    1. Hylek EM, Regan S, Go AS, et al. Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. Ann Intern Med. 2001;;135:393–400.
    1. Chu K, Wu SM, Stanley T, et al. A mutation in the propetide of Factor IX leads to warfarin sensitivity by a novel mechanism. J Clin Invest. 1996;;98:1619–1625.
    1. Glasheen JJ, Fugit RV, Prochazka AV. The risk of overanticoagulation with antibiotic use in outpatients on stable warfarin regimens. J Gen Intern Med. 2005;;20:653–656.
    1. Wittkowsky AK, Devine EB. Frequency and causes of overanticoagulation and underanticoagulation in patients treated with warfarin. Pharmacotherapy. 2004;;24:1311–1316.
    1. Samsa GP, Matchar DB, Goldstein LB, et al. Quality of anticoagulation management among patients with atrial fibrillation. Arch Intern Med. 2000;;160:967–973.
    1. Van Leeuwen Y, Rosendaal FR, Cannegieter SC. Prediction of hemorrhagic and thrombotic events in patients with mechanical heart valve prostheses treated with oral anticoagulants. J Thromb Haemost. 2008;;6:451–456.
    1. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med. 1993;;95:315–328.
    1. Hanley JP. Warfarin reversal. J Clin Pathol. 2004;;57:1132–1139.
    1. Aguilar MI, Hart RG, Kase CS, et al. Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinion. Mayo Clin Proc. 2007;;82:82–92.
    1. Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation. J Am Med Assoc. 2003;;290:2685–2692.
    1. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT) Lancet. 1996;;348:423–428.
    1. Schulman S, Beyth RJ, Kearon C, et al. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians evidence-based clinical practice guidelines (8th ed.) Chest. 2008;;133:257–298.
    1. Hylek EM, Evans-Molina C, Shea C, et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007;;115:2689–2696.
    1. Hylek EM, Chang Y, Skates SJ, et al. Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. Arch Intern Med. 2000;;160:1612–1617.
    1. McMahan DA, Smith DM, Carey MA, et al. Risk of major hemorrhage for outpatients treated with warfarin. J Gen Intern Med. 1998;;13:311–316.
    1. Makris M. Optimisation of the Prothrombin Complex Concentrate dose for warfarin reversal. Thromb Reversal. 2005;;115:451–453.
    1. White RH, McKittrick T, Hutchinson R, et al. Temporary discontinuation of warfarin therapy: changes in the international normalized ratio. Ann Intern Med. 1995;;122:40–42.
    1. Makris M, van Veen J, Maclean R. Warfarin anticoagulation reversal: management of the asymptomatic and bleeding patient. J Thromb Thrombolysis. 2010;;29:171–181.
    1. DeZee KJ, Shimeall WT, Douglas KM, et al. Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis. Arch Intern Med. 2006;;166:391–397.
    1. Makris M, Watson HG. The management of coumarin-induced over-anticoagulation. Br J Haematol. 2001;;114:271–280.
    1. Baker RI, Coughlin PB, Gallus AS, et al. Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. Med J Aust. 2004;;181:492–497.
    1. Dentali F, Crowther MA. Management of excessive anticoagulant effect due to vitamin K antagonists. Hematology. 2008. pp. 266–270.
    1. Levine M, Goldstein JN. Emergency warfarin reversal. In: Edardes JP, editor. Coumarin Anticoagulant Research Progress. New York, NY: Nova Science Publishers Inc;; 2008. pp. 1–9.
    1. Duguid J, O'Shaughnessy DF, Atterbury C, et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br Soc Haematol. 2004;;126:11–28.
    1. Lee SB, Manno EM, Layton KF, et al. Progression of warfarin-associated intracerebral hemorrhage after INR normalization with FFP. Neurology. 2006;;67:1272–1274.
    1. Bux J. Transfusion-related acute lung injury (TRALI): a serious adverse event of blood transfusion. Vox Sanguinis. 2005;;89:1–10.
    1. Khan H, Belsher J, Yilmaz M, et al. Fresh-frozen plasma and platelet transfusions are associated with development of acute lung injury in critically ill medical patients. Chest. 2007;;131:1308–1314.
    1. Dentali F, Ageno W, Crowther M. Treatment of coumarin-associated coagulopathy: a systematic review and proposed treatment algorithms. J Thromb Haemost. 2006;;4:1853–1863.
    1. Fredriksson K, Norrving B, Stromblad LG. Emergency reversal of anticoagulation after intracerebral hemorrhage. Stroke. 1992;;23:972–977.
    1. Rowe S, Turner RM. Coagulation Factor VIIa (recombinant) for warfarin-induced intracranial hemorrhage. Am J Health-Syst Pharm. 2010;;67:361–365.
    1. Rosovsky RP, Crowther MA. What is the evidence for the off-label use of recombinant Factor VIIa (rFVIIa) in the acute reversal of warfarin? Hematology. 2008. pp. 36–38.
    1. Sørensen B, Johansen P, Nielsen GL, et al. Reversal of the international normalized ratio with recombinant activated Factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects. Blood Coagulation Fibrinolysis. 2003;;14:469–477.
    1. Freeman WD, Brott TG, Barrett KM, et al. Recombinant Factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage. Mayo Clin Proc. 2004;;79:1495–1500.
    1. Brody DL, Aiyagari V, Shackleford AM, et al. Use of recombinant Factor VIIa in patients with warfarin-associated intracranial hemorrhage. Neurocrit Care. 2005;;2:263–267.
    1. Dager WE, King JH, Regalia RC, et al. Reversal of elevated international normalized ratios and bleeding with low-dose recombinant activated Factor VII in patients receiving warfarin. Pharmacology. 2006;;26:1091–1098.
    1. Safaoui M, Aazami R, Hotz H, et al. A promising new alternative for the rapid reversal of warfarin coagulopathy in traumatic intracranial hemorrhage. Am J Surg. 2009;;197:785–790.
    1. Aledort LM. Comparative thrombotic event incidence after infusion of recombinant Factor VIIa versus Factor VIII Inhibitor Bypassing Activity. J Thromb Haemost. 2004;;2:1700–1708.
    1. Tjønnfjord GE, Holme PA. Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in hemophilia patients with high-titer inhibitors. Vasc Health Risk Manage. 2007;;3:527–531.
    1. Wójcik C, Schymik ML, Cure EG. Activated prothrombin complex concentrate Factor VIII Inhibitor Bypassing Activity (FEIBA) for the reversal of warfarin-induced coagulopathy. Int J Emerg Med. 2009;;2:217–225.
    1. Holland L, Warkentin TE, Refaai M, et al. Suboptimal effect of a Three-Factor Prothrombin Complex Concentrate (Profilnin-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose. Transfusion. 2009;;49:1171–1177.
    1. Lubetsky A, Hoffman R, Zimlichman R, et al. Efficacy and safety of a Prothrombin Complex Concentrate (Octaplex) for rapid reversal of oral anticoagulation. Thromb Res. 2004;;113:371–378.
    1. Ostermann H, Haetrel S, Knaub S, et al. Pharmacokinetics of Beriplex P/N Prothrombin Complex Concentrate in healthy volunteers. Thromb Haemost. 2007;;98:790–797.
    1. Schulman S, Bijsterveld NR. Anticoagulants and their reversal. Transfusion Med Rev. 2007;;21:37–48.
    1. Makris M, Greaves M, Phillips WS, et al. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost. 1997;;77:477–480.
    1. Nitu IC, Perry DJ, Lee CA. Clinical experience with the use of clotting factor concentrates in oral anticoagulation reversal. Clin Lab Haematol. 1998;;20:363–367.
    1. van Aart L, Eijkhout HW, Kamphuis JS, et al. Individualized dosing regimen for Prothrombin Complex Concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: an open, prospective randomized controlled trial. Thromb Res. 2006;;118:313–320.
    1. Evans G, Luddington R, Baglin T. Beriplex P/N reverses severe warfarin-induced overanticoagulation immediately and completely in patients presenting with major bleeding. Br J Haematol. 2001;;115:998–1001.
    1. Lorenz R, Kienast J, Otto U, et al. Efficacy and safety of a Prothrombin Complex Concentrate with two virus-inactivation steps in patients with severe liver damage. Eur J Gastroenterol Hepatol. 2003;;15:15–20.
    1. Riess HB, Meier-Hellmann A, Motsch J, et al. Prothrombin Complex Concentrate (Octaplex) in patients requiring immediate reversal of oral anticoagulation. Thromb Res. 2007;;121:9–16.
    1. Cartmill M, Dolan G, Byrne JL, et al. Prothrombin Complex Concentrate for oral anticoagulant reversal in neurosurgical emergencies. Br J Neurosurg. 2000;;14:458–461.
    1. Leissinger CA, Blatt PM, Hoots WK, et al. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. Am J Hematol. 2008;;83:137–143.
    1. Levy JH, Tanaka KA, Dietrich W. Perioperative hemostatic management of patients treated with vitamin K antagonists. Anesthesiology. 2008;;109:918–926.
    1. Preston FE, Laidlaw ST, Sampson B, et al. Rapid reversal of oral anticoagulation with warfarin by a Prothrombin Complex Concentrate (Beriplex): efficacy and safety in 42 patients. Br J Haematol. 2002;;116:619–624.
    1. Yasaka M, Sakata T, Naritomi H, et al. Optimal dose of Prothrombin Complex Concentrate for acute reversal of oral anticoagulation. Thromb Res. 2005;;115:455–459.
    1. Liumbruno G, Bennardello F, Lattanzio A, et al. Recommendations for the use of antithrombin concentrates and Prothrombin Complex Concentrates. Blood Transfusion. 2009;;7:325–334.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever